The Company's principal product under development, MS-325, is an injectable intravascular contrast agent designed for multiple cardiovascular imaging applications, including peripheral vascular disease and coronary artery disease. MS-325 is a small molecule that produces an MRI signal by containing gadolinium, a highly magnetically active element used for enhancing magnetic resonance images. This molecule is designed with the Company's proprietary technology to bind to albumin, a common blood protein. In MS-325 images using standard MRI techniques, the blood gives off a strong magnetic signal and appears bright against the dark background of surrounding tissue. Results reflect the development funding terms under the Schering agreement.
Higher loss reflects higher legal and personnel costs.
All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Data and information is provided for informational purposes only, and is not intended for trading purposes.